For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
- Brief patient counseling information can be found in the Dalteparin (Fragmin) package insert
- Dalteparin (Fragmin) patient drug information (UpToDate)
History of changes in FDA indication
- 12/22/1994: Initial approval for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip replacement surgery.
- Subsequently approved for prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness and extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months.
- 5/16/2019: Approved to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older.
Also known as
- Brand names: Daltepan, Daltepin, Fluzepamin, Fragmin, Fragmine, Fragminject, Fresubaru, Hepachron, Hepagumin, Ligofragmin, Low Liquemin, Resolmin